Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

[18F]FDG PET/CT in mucosal melanoma lesional metabolic activity predicts progression.

Created on 20 Jul 2026

Authors

Zhi Lin, Cheng Tang, Tong Liu, Xingyi Wang, Fan Hu, Xiao Zhang, Xiaoli Lan

Published in

European journal of nuclear medicine and molecular imaging. Jul 20, 2026. Epub Jul 20, 2026.

Abstract

This study investigates the prognostic value of [18F]FDG PET/CT-derived parameters in predicting PFS and OS in mucosal melanoma patients.
This single-center retrospective study included 58 patients with primary mucosal melanoma who underwent [18F]FDG PET/CT imaging. PET/CT parameters (SUVmax, SUVr, WBMTV, WBTLG) were extracted from delineated lesions. Kaplan-Meier curves, ROC analysis, and univariate and multivariate Cox regression were used to assess predictive performance and identify prognostic factors for PFS and OS.
The median follow-up was 15 months (range: 1-48 months). Disease progression occurred in 47 patients (median PFS = 8.0 months, 95% CI: 7.0-11.0 months), and 30 patients died (median OS = 18.0 months, 95% CI: 15.0 months - NE). ROC analysis showed all [18F]FDG PET/CT parameters (SUVmax, SUVr, WBMTV and WBTLG) could predicted progression and mortality (all p < 0.01). The optimal cutoff value of SUVmax for predicting disease progression was 10.8 g/ml; the optimal cutoff value of WBMTV for predicting mortality was 14.1 cm3. In univariate COX analysis, SUVmax and SUVr were significantly linked to both PFS and OS (both p < 0.05), while WBMTV and WBTLG only correlated with OS (both p < 0.01). Multivariate analysis identified SUVmax as an independent predictor of PFS (HR = 1.04, p < 0.05) and WBMTV as an independent predictor of OS (HR = 2.15, p < 0.05).
[18F]FDG PET/CT parameters can aid in risk stratification and treatment decisions for mucosal melanoma. SUVmax predicts disease progression, while WBMTV forecasts overall survival.

PMID:
42472724
Bibliographic data and abstract were imported from PubMed on 20 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement